Simplification of HAART therapy on ambulatory HIV patients in Malaysia: A randomized controlled trial

Tineshwaran Velvanathan, Farida Hanim Islahudin, Benedict L H Sim, Nur Akmar Taha

Research output: Contribution to journalArticle

Abstract

Objective: Evaluate the impact of fixed-dose combination (FDC) containing emtricitabine (FTC), tenofovir (TDF), and efavirenz (EFV) versus a free-dose combination (FRC) of the same three drugs on clinical outcomes, adherence and quality of life in Malaysian outpatients with HIV. Methods: HIV patients (n=120) on highly active antiretroviral therapy (HAART) in the infectious disease clinic of Hospital Sungai Buloh were randomized to either FDC (n=60) or FRC (n=60). Morisky scores, health-related quality of life scores and clinical outcomes such as CD4 count and viral load were assessed in both groups at baseline and six months. Result: Patients on FDC (108 SD=1.1) had a significantly higher CD4 count increase compared to the FRC group (746.1 SD=36.3 vs 799.8 SD=33.8) (p <0.001). The viral load profile was unchanged and remained undetectable in both groups. The quality of life EQ-5D scores showed a positive correlation with CD4 counts in the FDC group (ρ=0.301, p=0.019) at six months. On the other hand, quality of life EQ-VAS scores was significantly associated with medication adherence in the FDC group at six months (ρ=0.749, p=0.05). However, no significant changes or associations were observed in the FRC group. Conclusion: Management of HAART using an FDC demonstrated a positive clinical outcome, adherence and quality of life within six months in local HIV patients.

Original languageEnglish
Article number830
JournalPharmacy Practice
Volume14
Issue number4
DOIs
Publication statusPublished - 1 Oct 2016

Fingerprint

Tenofovir
efavirenz
Malaysia
Highly Active Antiretroviral Therapy
Randomized Controlled Trials
Quality of Life
Health
HIV
CD4 Lymphocyte Count
Pharmaceutical Preparations
Viral Load
Therapeutics
Medication Adherence
Communicable Diseases
Outpatients
Emtricitabine

Keywords

  • Anti-retroviral agents
  • Antiretroviral therapy
  • Benzoxazines
  • CD4 lymphocyte count
  • Drug combinations
  • Emtricitabine
  • Highly active
  • Malaysia
  • Tenofovir
  • Viral load

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Simplification of HAART therapy on ambulatory HIV patients in Malaysia : A randomized controlled trial. / Velvanathan, Tineshwaran; Islahudin, Farida Hanim; Sim, Benedict L H; Taha, Nur Akmar.

In: Pharmacy Practice, Vol. 14, No. 4, 830, 01.10.2016.

Research output: Contribution to journalArticle

@article{bb8d23bc582a46ffaa449ae4952fc3ff,
title = "Simplification of HAART therapy on ambulatory HIV patients in Malaysia: A randomized controlled trial",
abstract = "Objective: Evaluate the impact of fixed-dose combination (FDC) containing emtricitabine (FTC), tenofovir (TDF), and efavirenz (EFV) versus a free-dose combination (FRC) of the same three drugs on clinical outcomes, adherence and quality of life in Malaysian outpatients with HIV. Methods: HIV patients (n=120) on highly active antiretroviral therapy (HAART) in the infectious disease clinic of Hospital Sungai Buloh were randomized to either FDC (n=60) or FRC (n=60). Morisky scores, health-related quality of life scores and clinical outcomes such as CD4 count and viral load were assessed in both groups at baseline and six months. Result: Patients on FDC (108 SD=1.1) had a significantly higher CD4 count increase compared to the FRC group (746.1 SD=36.3 vs 799.8 SD=33.8) (p <0.001). The viral load profile was unchanged and remained undetectable in both groups. The quality of life EQ-5D scores showed a positive correlation with CD4 counts in the FDC group (ρ=0.301, p=0.019) at six months. On the other hand, quality of life EQ-VAS scores was significantly associated with medication adherence in the FDC group at six months (ρ=0.749, p=0.05). However, no significant changes or associations were observed in the FRC group. Conclusion: Management of HAART using an FDC demonstrated a positive clinical outcome, adherence and quality of life within six months in local HIV patients.",
keywords = "Anti-retroviral agents, Antiretroviral therapy, Benzoxazines, CD4 lymphocyte count, Drug combinations, Emtricitabine, Highly active, Malaysia, Tenofovir, Viral load",
author = "Tineshwaran Velvanathan and Islahudin, {Farida Hanim} and Sim, {Benedict L H} and Taha, {Nur Akmar}",
year = "2016",
month = "10",
day = "1",
doi = "10.18549/PharmPract.2016.04.830",
language = "English",
volume = "14",
journal = "Pharmacy Practice",
issn = "1885-642X",
publisher = "Centro de Investigaciones y Publicaciones Farmaceuticas",
number = "4",

}

TY - JOUR

T1 - Simplification of HAART therapy on ambulatory HIV patients in Malaysia

T2 - A randomized controlled trial

AU - Velvanathan, Tineshwaran

AU - Islahudin, Farida Hanim

AU - Sim, Benedict L H

AU - Taha, Nur Akmar

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Objective: Evaluate the impact of fixed-dose combination (FDC) containing emtricitabine (FTC), tenofovir (TDF), and efavirenz (EFV) versus a free-dose combination (FRC) of the same three drugs on clinical outcomes, adherence and quality of life in Malaysian outpatients with HIV. Methods: HIV patients (n=120) on highly active antiretroviral therapy (HAART) in the infectious disease clinic of Hospital Sungai Buloh were randomized to either FDC (n=60) or FRC (n=60). Morisky scores, health-related quality of life scores and clinical outcomes such as CD4 count and viral load were assessed in both groups at baseline and six months. Result: Patients on FDC (108 SD=1.1) had a significantly higher CD4 count increase compared to the FRC group (746.1 SD=36.3 vs 799.8 SD=33.8) (p <0.001). The viral load profile was unchanged and remained undetectable in both groups. The quality of life EQ-5D scores showed a positive correlation with CD4 counts in the FDC group (ρ=0.301, p=0.019) at six months. On the other hand, quality of life EQ-VAS scores was significantly associated with medication adherence in the FDC group at six months (ρ=0.749, p=0.05). However, no significant changes or associations were observed in the FRC group. Conclusion: Management of HAART using an FDC demonstrated a positive clinical outcome, adherence and quality of life within six months in local HIV patients.

AB - Objective: Evaluate the impact of fixed-dose combination (FDC) containing emtricitabine (FTC), tenofovir (TDF), and efavirenz (EFV) versus a free-dose combination (FRC) of the same three drugs on clinical outcomes, adherence and quality of life in Malaysian outpatients with HIV. Methods: HIV patients (n=120) on highly active antiretroviral therapy (HAART) in the infectious disease clinic of Hospital Sungai Buloh were randomized to either FDC (n=60) or FRC (n=60). Morisky scores, health-related quality of life scores and clinical outcomes such as CD4 count and viral load were assessed in both groups at baseline and six months. Result: Patients on FDC (108 SD=1.1) had a significantly higher CD4 count increase compared to the FRC group (746.1 SD=36.3 vs 799.8 SD=33.8) (p <0.001). The viral load profile was unchanged and remained undetectable in both groups. The quality of life EQ-5D scores showed a positive correlation with CD4 counts in the FDC group (ρ=0.301, p=0.019) at six months. On the other hand, quality of life EQ-VAS scores was significantly associated with medication adherence in the FDC group at six months (ρ=0.749, p=0.05). However, no significant changes or associations were observed in the FRC group. Conclusion: Management of HAART using an FDC demonstrated a positive clinical outcome, adherence and quality of life within six months in local HIV patients.

KW - Anti-retroviral agents

KW - Antiretroviral therapy

KW - Benzoxazines

KW - CD4 lymphocyte count

KW - Drug combinations

KW - Emtricitabine

KW - Highly active

KW - Malaysia

KW - Tenofovir

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=85006961521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006961521&partnerID=8YFLogxK

U2 - 10.18549/PharmPract.2016.04.830

DO - 10.18549/PharmPract.2016.04.830

M3 - Article

AN - SCOPUS:85006961521

VL - 14

JO - Pharmacy Practice

JF - Pharmacy Practice

SN - 1885-642X

IS - 4

M1 - 830

ER -